Clinically determined CIO (N = 190) | Geometric mean of hearing thresholds (N = 200) | |||||
---|---|---|---|---|---|---|

Cases (N = 37) | Controls (N = 153) | P value | Cases (N = 33) | Controls (N = 167) | P value | |

Age at time of treatment (years), median (IQR) | 40 (32–49) | 29 (23–35) | 3.00 × 10^{−7} | 40 (31–51) | 30 (24–35) | 3.11 × 10^{−7} |

Cumulative cisplatin dose (mg/m^{2}), median (min, max) | 400 (300–920) | 400 (300–800) | 0.005 | 400 (200–920) | 400 (200–900) | 0.012 |

Concomitant ototoxic medication,^{a}n (%) | 1 (2.7) | 4 (2.6) | 1.000 | 1 (3.0) | 6 (3.6) | 1.000 |

Cranial irradiation, n (%) | 1 (2.7) | 2 (1.3) | 0.480 | 1 (3.0) | 1 (0.6) | 0.304 |

Cancer treatment protocol | 0.078 | 0.012 | ||||

BEP, n (%) | 17 (45.9) | 102 (66.7) | 0.024 | 14 (42.4) | 114 (68.3) | 0.009 |

EP, n (%) | 13 (35.1) | 32 (20.9) | 0.085 | 11 (33.3) | 32 (19.2) | 0.038 |

VIP2, n (%) | 1 (2.7) | 6 (3.9) | 1.000 | 1 (3.0) | 8 (4.8) | 0.357 |

Combination, n (%) | 6 (16.2) | 13 (8.5) | 0.217 | 7 (21.2) | 13 (7.8) | 0.028 |

Proportion ancestry European, median IQR) | 0.85 (0.81–0.90) | 0.81 (0.70–0.87) | 0.018 | 0.85 (0.81-0.91) | 0.81 (0.70- 0.87) | 0.036 |

East Asian, median (IQR) | 0.02 (0.00–0.04) | 0.01 (0.00- 0.05) | 0.636 | 0.02 (0.00–0.04) | 0.01 (0.00–0.05) | 0.190 |

South Asian, median (IQR) | 0.08 (0.03- 0.14) | 0.07 (0.02–0.12) | 0.564 | 0.08 (0.03–0.14) | 0.07 (0.02–0.12) | 0.253 |

American, median (IQR) | 0.01 (0.00–0.05) | 0.02 (0.00–0.05) | 0.167 | 0.01 (0.00–0.05) | 0.02 (0.00–0.05) | 0.102 |

African, median (IQR) | 0.02 (0.00–0.03) | 0.03 (0.02–0.05) | 0.075 | 0.02 (0.00–0.03) | 0.03 (0.01–0.05) | 0.077 |

BEP: 20 mg/m

^{2}cisplatin, 100 mg/m^{2}etoposide, 30 units bleomycin for 5 days per cycle; EP: 20 mg/m^{2}cisplatin, 100 mg/m^{2}etoposide for 5 days per cycle, IQR: interquartile range; max: maximum; min: minimum; VIP2: 20 mg/m^{2}cisplatin, 75 mg/m^{2}etoposide, 1500 mg/m^{2}ifos, 300 mg/m^{2}mesna for 5 days per cycle.↵

^{a}Tobramycin, vancomycin, vincristine, furosemide. Significant*P*values (*P*< 0.05) are bolded. Proportion ancestry was calculated using ADMIXTURE, including five ancestral components.